TaiGen Biopharmaceuticals Holdings Limited (4157)

Overview

TaiGen Biopharmaceuticals Holdings Limited is a Taipei City, Taiwan-based pharmaceutical company, founded in 2001, that focuses on the development of novel therapeutics aimed at treating transformative diseases on a global scale. The company is known for its commitment to addressing the unmet medical needs in various therapeutic areas, including infectious diseases, stem cell mobilization, influenza, and chronic hepatitis C, through its innovative research and drug development initiatives.

Products and Services

• Taigexyn (Nemonoxacin) - A non-fluorinated quinolone antibiotic designed for the treatment of bacterial infections. Unlike traditional antibiotics, Taigexyn offers a new approach to combating bacterial infections, including those resistant to other antibiotics.

  Currently, Taigexyn is being developed for additional indications, such as community-acquired pneumonia and diabetic foot infections, offering hope for more effective treatment options in these areas.

• Burixafor - A stem cell mobilizer that is under development for use in stem cell transplantation and chemosensitization.

  This promising compound aims to improve the efficacy of stem cell collection processes and enhance the effectiveness of chemotherapeutic treatments by mobilizing stem cells.

• TG-1000 - An antiviral drug targeting influenza, including strains A, B, and the avian influenza H7N9.

  TG-1000 represents a crucial advancement in the fight against seasonal and pandemic influenza, offering potential for more effective prevention and treatment strategies.

• Furaprevir - A protease inhibitor targeting the hepatitis C virus (HCV), intended for the treatment of chronic hepatitis C.

  Furaprevir offers a new mechanism of action in the management of HCV, potentially improving treatment outcomes for patients suffering from this chronic condition.